SIREN : 424347011
JAZZ PHARMACEUTICALS FRANCE is a French company founded 26 years ago, specialized in the sector Activités des sièges sociaux. Based in LYON (69006), this company of category ETI shows in 2024 a revenue of 93.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 93 642 087 € | 87 111 090 € | 72 467 442 € | 58 615 232 € | 87 694 302 € | 100 574 049 € | 86 462 614 € | 95 158 185 € | N/C |
| Net income | 8 522 335 € | 11 253 370 € | 8 775 852 € | 13 650 726 € | 55 491 522 € | 10 280 994 € | 11 222 764 € | 21 570 716 € | 20 603 322 € |
| EBITDA | 17 409 245 € | 16 871 398 € | 19 140 304 € | 19 313 724 € | 31 834 314 € | 36 558 404 € | 28 056 197 € | 32 968 868 € | -59 595 762 € |
| Net margin | 9.1% | 12.9% | 12.1% | 23.3% | 63.3% | 10.2% | 13.0% | 22.7% | N/C |
In 2024, JAZZ PHARMACEUTICALS FRANCE achieves revenue of 93.6 M€. Activity remains stable over the period (CAGR: -0.2%). Vs 2023: +7%. After deducting consumption (23.3 M€), gross margin stands at 70.4 M€, i.e. a rate of 75%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 17.4 M€, representing 18.6% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 8.5 M€, i.e. 9.1% of revenue. This profit can be retained or distributed to shareholders.
93 642 087 €
70 388 114 €
17 409 245 €
11 789 331 €
8 522 335 €
18.6%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 28%. The balance between equity and debt is satisfactory. Cash flow represents 9.9% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
0.0%
28.447%
9.895%
0.0
2.4%
In 2024, the debt ratio of JAZZ PHARMACEUTICALS FRANCE (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of JAZZ PHARMACEUTICALS FRANCE (28.4%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of JAZZ PHARMACEUTICALS FRANCE (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 118.19. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
118.194
0.0
In 2024, the liquidity ratio of JAZZ PHARMACEUTICALS FRANCE (118.19) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of JAZZ PHARMACEUTICALS FRANCE (0.0x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 108 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 224 days. Excellent situation: suppliers finance 116 days of the operating cycle (retail model). Inventory turnover is 25 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 194 days of revenue, i.e. 50.4 M€ to permanently finance.
50 411 281 €
108 j
224 j
25 j
194 j
Based on 103 transactions of similar company sales in 2024, the value of JAZZ PHARMACEUTICALS FRANCE is estimated at 70 609 904 € (range 18 159 870€ - 137 514 144€). With an EBITDA of 17 409 245€, the sector multiple of 5.0x is applied. The price/revenue ratio is 0.38x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 103 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare JAZZ PHARMACEUTICALS FRANCE with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sièges sociaux
The revenue of JAZZ PHARMACEUTICALS FRANCE in 2024 is 93.6 M€.
Yes, JAZZ PHARMACEUTICALS FRANCE generated a net profit of 8.5 M€ in 2024.
The headquarters of JAZZ PHARMACEUTICALS FRANCE is located in LYON (69006), in the department Rhone.
The tax return of JAZZ PHARMACEUTICALS FRANCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
JAZZ PHARMACEUTICALS FRANCE operates in the sector Activités des sièges sociaux (NAF code 70.10Z). See the 'Sector positioning' section above to compare the company with its competitors.